Latest News

FDA signals accelerated path for givastomig in CLDN18.2+ gastric/GEJ cancer, as phase 1b data show strong responses and tolerability.

A 31-gene expression profile–based sentinel lymph node biopsy risk model, i31-SLNB, demonstrated a role in predicting lymph node positivity in T1b to T2a melanoma.

Oncology shifts fast: tazemetostat pulled, giredestrant PFS miss, and new ADC and NSCLC guideline strategies refine metastatic care.

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment.

Report finds hospitals price the same cancer drugs up to 2000x apart, worsening financial toxicity and intensifying demands for real transparency.

Denileukin diftitox brings a new systemic option for relapsed CTCL, killing tumor cells and Tregs to boost immunity and expand EU access.

Interim phase 1b results show off-the-shelf CD19 CAR T azer-cel drives high response rates in hard-to-treat CLL/SLL and MZL.

Fifty patients are enrolled to receive EBX-102-02 or placebo to address gut microbiome disruption associated with allogeneic hematopoietic cell transplant.

Breast cancer care shifts fast: ADCs reach HER2-low, neoadjuvant regimens evolve, and ctDNA MRD testing sparks 2026’s debate.

During a live event, Daniel Olson, MD, reviewed a patient case of recurrent melanoma with brain metastases and addressed treatment options.

A validated analysis of nearly 22,000 patients receiving allogeneic hematopoietic cell transplant led to development of a risk calculator for acute graft-vs-host disease.

Sacituzumab govitecan plus pembrolizumab may enable bladder preservation in MIBC.

AI plus digital pathology and clinical data pinpoint HR+/HER2- early breast cancers with unexpectedly low distant recurrence, sharpening prognosis and guiding endocrine or chemo choices.

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Gedatolisib plus fulvestrant, with or without palbociclib, boosts PFS in HR+/HER2− PIK3CA WT breast cancer after CDK4/6.

IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.

Ipsen pulls Tazverik worldwide after SYMPHONY-1 flags secondary blood cancer risk, halting trials and access programs and moving patients to standard care.

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

How GLP-1 weight-loss drugs fit after breast cancer: emerging survival hints, new ESMO cautions during chemo, and smart tapering to avoid rebound.

The CYTOSHRINK trial showed that incorporating stereotactic body radiation therapy (SBRT) with ipilimumab and nivolumab did not enhance progression-free survival and resulted in a shorter median PFS compared to immunotherapy alone for advanced renal cell carcinoma.

Long-term CheckMate 9ER results show deeper tumor shrinkage with cabozantinib plus nivolumab and predicts longer survival and durable responses in advanced renal cell carcinoma.

An interview with Joshua Reuss, MD, thoracic medical oncologist at Georgetown University and co-author of the guidelines.

A phase 3 trial evaluating TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) showed positive safety and toxicity profile in prostate cancer.

Academic centers are associated with greater biliary tract cancer surgery success while minority patients and nonacademic care face gaps, urging better resource allocation.

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

A supplemental Biologics License Application has been submitted for nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors.

Results from the 992-patient study will be presented at an upcoming medical meeting; FDA review of giredestrant is ongoing based on data from the positive evERA trial.

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

The addition of the CELMoD mezigdomide to carfilzomib and dexamethasone led to progression-free survival improvement in relapsed/refractory multiple myeloma.

Compare T-DXd, sacituzumab, and dato-DXd in HR+ metastatic breast cancer—key trial results, side effects, and sequencing insights.

PIM-1 kinase inhibitors in myelofibrosis offer new targets to overcome relapsed and refractory disease.